8-KLeadership ChangesRegulation FDExhibits & Filings

GE HealthCare Technologies Inc. 8-K Report, Executive Changes (Mar 17, 2026)

Filed March 17, 2026For Securities:GEHC

Summary

GE HealthCare Technologies Inc. announced a change to its Board of Directors via an 8-K filing on March 17, 2026. The company appointed Kevin A. Lobo as a new director and a member of the Talent, Culture, and Compensation Committee, effective March 13, 2026. Mr. Lobo's appointment is not the result of any disagreements or arrangements with other parties and will not trigger any reportable transactions under SEC regulations. Investors should note that Mr. Lobo will receive standard compensation for non-employee directors. Additionally, the filing disclosed that Risa Lavizzo-Mourey and Tomislav Mihaljevic will not seek re-election at the upcoming 2026 Annual Meeting of Stockholders. Their decisions are attributed to other commitments and not to any disputes with the company. These board changes, particularly the addition of Mr. Lobo, could signal a focus on executive oversight and compensation strategy.

Key Highlights

  • 1Kevin A. Lobo appointed to the Board of Directors and the Talent, Culture, and Compensation Committee.
  • 2Mr. Lobo's appointment is effective immediately and his term expires at the 2026 Annual Meeting of Stockholders.
  • 3Risa Lavizzo-Mourey and Tomislav Mihaljevic will not stand for re-election to the Board.
  • 4The departures of Dr. Lavizzo-Mourey and Dr. Mihaljevic are due to other commitments and not disagreements.
  • 5Mr. Lobo will be compensated according to the company's non-employee director compensation program.
  • 6No arrangements or reportable transactions (Item 404(a)) exist between Mr. Lobo and the Company.
  • 7The press release announcing Mr. Lobo's appointment was issued on March 17, 2026.

Frequently Asked Questions

Kevin A. Lobo has been appointed as a new director and a member of the Talent, Culture, and Compensation Committee. The filing does not provide details on his professional background but states his appointment is effective immediately and he will receive standard director compensation. His selection was not based on any specific arrangement with other parties.

Dr. Risa Lavizzo-Mourey and Dr. Tomislav Mihaljevic have informed the Board that they will not seek re-election at the 2026 Annual Meeting of Stockholders. The company states this decision is due to other commitments and not a result of any disagreements regarding the company's operations, policies, or practices.

Mr. Lobo has been appointed to the Talent, Culture, and Compensation Committee. While his appointment to this committee suggests an involvement in compensation matters, the filing does not explicitly state that his appointment will lead to immediate changes in executive compensation policies. His compensation as a director will follow the existing program.

The filing indicates that Mr. Lobo will be compensated under the existing non-employee director program, and there are no reportable transactions or disagreements associated with his appointment. The departures of Dr. Lavizzo-Mourey and Dr. Mihaljevic are also stated as not being due to disagreements. Therefore, at this time, no direct negative financial implications are indicated for the company as a result of these board changes.